59th ASH Annual Meeting & Exposition

59th ASH Annual Meeting & Exposition:

The Premier Event in Malignant and Non-malignant Hematology

The American Society of Hematology (ASH) Annual Meeting, the world’s most important gathering of hematologists, showcases thousands of scientific abstracts highlighting updates in the hottest topics in hematology. Over 25,000 hematology professionals from every subspecialty were present at this meeting, including many of our MCRN researchers who presented their abstracts orally or through posters. Kudos to our world-class Canadian team for putting Canadian talent on the map!

Poster and oral presentations presented by our MCRN researchers to the global community were as follows:

ORAL PRESENTATIONS

Deep and Durable Responses in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (MM) Treated with Monotherapy GSK2857916, an Antibody Drug Conjugate Against B-Cell Maturation Antigen (BCMA): Preliminary Results from Part 2 of Study BMA117159

Presenter: Dr Suzanne Trudel, University of Toronto

Single Cell Resolution Profiling Defines the Innate and Adaptive Immune Repertoires Modulated By Daratumumab and IMiDs Treatment in Multiple Myeloma (MM)

Presenter: Dr Paola Neri, University of Calgary

Picture left: Dr Neri during her presentation at ASH

Transcriptional Plasticity Compensates for Ikaros and Aiolos Proteasomal Degradation and Mediates Resistance to IMiDs in Multiple Myeloma (MM)

Presenter: Dr Paola Neri, University of Calgary

POSTER PRESENTATIONS

Selinexor in Combination with Weekly Low Dose Bortezomib and Dexamethasone (SVd) Induces a High Response Rate with Durable Responses in Patients with Refractory Multiple Myeloma (MM)

Presenter: Dr Nizar Bahlis, University of Calgary

Selinexor in Combination with Pomalidomide and Low Dose Dexamethasone in a Relapsed / Refractory Multiple Myeloma Patient Population with Prior Proteasome Inhibitor and Lenalidomide Exposure

Presenter: Dr Christine Chen, University of Toronto

Bortezomib Consolidation after Nonmyeloablative Allogeneic Transplant Is Safe and Leads to a High Incidence of Immunophenotypic Complete Response in High-Risk or Young Myeloma Patients

Presenter: Dr Richard LeBlanc, Université de Montréal

Impact of Active Maintenance Treatment (MT) Compared to No MT on the Quality of Life (QoL) of Patients with Multiple Myeloma (MM) Following First Autologous Stem Cell Transplant (ASCT)

Presenter: Dr Jason Tay, University of Ottawa

A Phase Ib/II Trial of Selinexor Combined with Lenalidomide and Low Dose Dexamethasone in Patients with Relapsed / Refractory Multiple Myeloma

Presenter: Dr Darrell White, Dalhousie University

Real World Outcomes of Newly Diagnosed High-Risk Multiple Myeloma Patients Treated at Princess Margaret Cancer Centre: A Retrospective Chart Review

Presenter: Dr Donna Reece, University of Toronto

Detection of Minimal Residual Disease in Autograft Is Prognostic of Survival Following Stem Cell Transplant in Multiple Myeloma

Presenter: Dr Michael Chu, University of Alberta

Minimal Residual Disease (MRD) Assessed By Flow Cytometry in Patients with AL Amyloidosis Treated with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD)

Presenter: Dr Victor Jimenez-Zepeda, University of Calgary

Bortezomib-Maintenance for Patients with AL Amyloidosis: A Single Center Experience

Presenter: Dr Victor Jimenez-Zepeda, University of Calgary